BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore). 2016;95:e2831. [PMID: 26937912 DOI: 10.1097/md.0000000000002831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Seyedmajidi MR, Hosseini SA, Vafaeimanesh J. Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating Helicobacter Pylori. Middle East J Dig Dis 2021;13:131-8. [PMID: 34712451 DOI: 10.34172/mejdd.2021.216] [Reference Citation Analysis]
2 Yilmaz B, Koseoglu H, Coskun Y, Deveci M, Kekilli M. Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance. Prz Gastroenterol 2018;13:150-6. [PMID: 30002775 DOI: 10.5114/pg.2018.72732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint. World J Gastroenterol 2017; 23(37): 6920-6922 [PMID: 29085236 DOI: 10.3748/wjg.v23.i37.6920] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect 2020;9:1180-93. [PMID: 32498615 DOI: 10.1080/22221751.2020.1769500] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
5 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
6 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
7 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
8 Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. Microbiologyopen 2020;9:e1120. [PMID: 33026166 DOI: 10.1002/mbo3.1120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Markwart R, Willrich N, Haller S, Noll I, Koppe U, Werner G, Eckmanns T, Reuss A. The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control 2019;8:147. [PMID: 31485325 DOI: 10.1186/s13756-019-0594-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
10 Hosseini RS, Rahimian G, Shafigh MH, Validi M, Khaledi M, Gholipour A. Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. AMB Express 2021;11:147. [PMID: 34731345 DOI: 10.1186/s13568-021-01310-9] [Reference Citation Analysis]
11 Miftahussurur M, Aftab H, Shrestha PK, Sharma RP, Subsomwong P, Waskito LA, Doohan D, Fauzia KA, Yamaoka Y. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control 2019;8:40. [PMID: 30815255 DOI: 10.1186/s13756-019-0482-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
12 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
13 Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 White B, Sterrett JD, Grigoryan Z, Lally L, Heinze JD, Alikhan H, Lowry CA, Perez LJ, DeSipio J, Phadtare S. Characterization of gut microbiome and metabolome in Helicobacter pylori patients in an underprivileged community in the United States. World J Gastroenterol 2021; 27(33): 5575-5594 [PMID: 34588753 DOI: 10.3748/wjg.v27.i33.5575] [Reference Citation Analysis]
15 Farzi N, Behzad C, Hasani Z, Alebouyeh M, Zojaji H, Zali MR. Characterization of clarithromycin heteroresistance among Helicobacter pylori strains isolated from the antrum and corpus of the stomach. Folia Microbiol (Praha) 2019;64:143-51. [PMID: 30097895 DOI: 10.1007/s12223-018-0637-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med 2020;14:43-50. [PMID: 31907860 DOI: 10.1007/s11684-019-0706-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
17 Vente A, Bentley C, Lückermann M, Tambyah P, Dalhoff A. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates. Antimicrob Agents Chemother 2018;62:e02325-17. [PMID: 29339393 DOI: 10.1128/AAC.02325-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]